Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat Media Wall Street Loves FIGS—Why Do Price Targets Predict Pullback?Submitted by Jennifer Ryan Woods. Originally Published: 3/4/2026. 
Key Takeaways - FIGS stock has surged nearly 260% over the past year, hitting a price not seen since shortly after its 2021 IPO.
- Q4 revenue topped $200 million—the company's best quarter ever—with scrubwear sales up 35% and international sales jumping 55%.
- Despite the rally and bullish analyst commentary, the consensus price target sits almost 30% below current levels.
After a steep decline following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has staged a dramatic comeback, trading at levels it hasn't seen in nearly four years. The stock, now above $17, has climbed almost 260% over the past year, including a roughly 58% gain in the last month. The rally has been driven by strong earnings and a wave of bullish analyst commentary. Yet the consensus 12-month price target for FIGS remains just $12.25—almost 30% below the current price. That gap raises the question: how much of this recovery is supported by fundamentals and how much is momentum? A look at FIGS' history and recent results provides some perspective. Ticker reveale - the ONE stock to buy today
After analyzing over 3,000 stocks and a staggering 40,169 data points... NYSE:???? is the No. 1 stock my team recommends buying today. In fact, according to our research, we believe this is one stock Warren Buffett himself would buy today - if he could. Why did Buffett really step down? Early investors enjoyed a quick windfall after the company's May 2021 IPO at $22 per share; within a month the stock spiked to $50. Demand during the COVID-19 pandemic helped fuel that surge. As the pandemic eased, however, shares reversed sharply and fell below $8 within a year. For the next few years FIGS traded mostly in the single digits, dipping below $4 in April 2025 before beginning its most recent run higher. Earnings Momentum Sparks Rally Steady gains after positive Q1 and Q2 2025 earnings reports accelerated following the Q3 2025 results released on Nov. 6. That report delivered stronger-than-expected revenue growth, broad demand across the core business and healthy margins despite tariff headwinds. FIGS also raised its full-year guidance for net revenue and adjusted EBITDA margins, which helped push the stock more than 30% higher over the subsequent week and prompted Zacks Research to upgrade the stock to Strong Buy from Hold. The momentum continued after the Q4 2025 earnings report on Feb. 26. The company posted a 33% jump in revenue—its best quarterly sales yet, topping $200 million—and highlighted growth in its active customer base and higher average order values. FIGS also noted a high-profile achievement by outfitting Team USA's medical team during the Winter Olympics. Scrubwear remained the core strength, accounting for more than three-quarters of net revenue and rising 35%. International sales climbed 55%, contributing to a record $630 million in net revenue for the year, up 14% year-over-year. Despite tariff pressures that affected gross margins, profitability held up: full-year adjusted EBITDA margin beat the company's target by more than 200 basis points. Analysts Applaud Earnings and Outlook FIGS issued a constructive outlook for fiscal 2026, expecting net revenue to grow 10% to 12% and signaling improved profitability targets. Management also highlighted plans to expand into new international markets, prioritize growth across business lines and continue its stock buyback program. Analysts responded with a flurry of upgrades and tweaks. Barclays moved to Strong Buy from Hold, KeyCorp shifted to Overweight from Sector Weight with a $17 target, and Goldman Sachs adjusted its view to Hold from Strong Sell. BTIG reiterated a Buy rating with a $15 target, and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets Strong earnings clearly propelled FIGS to four-year highs. Shares had already been climbing before the Q4 report—rising nearly 14% in the session ahead of the release—and the rally intensified afterward, with a 24% jump on the first trading day following the results and another 10% the next day. As of March 4, the stock was trading above $17, well above Morgan Stanley's $8 target from January and matching the highest target of $17 set by KeyCorp. The gap between rising analyst enthusiasm and relatively low price targets suggests analysts like the improving fundamentals but remain cautious about valuation. At current levels, FIGS trades at a price-to-earnings ratio near 90, implying much of the company's expected growth may already be priced in. There are few publicly traded direct competitors to FIGS. By contrast, lululemon athletica inc. (NASDAQ: LULU)—a dominant lifestyle apparel player—is trading at a P/E of less than 12. The takeaway: investors are rewarding FIGS' turnaround, but skepticism remains about whether the stock can sustain this pace or if a pullback is likely.
| 
